PODCAST

CME

ReachMD

science & medicine medicine

All Episodes

00:13:45

When Topicals Fail: The New IPC Consensus Every...

CME ·

2025/12/22

Faculty: Linda Stein Gold, MD Faculty: Bruce Strober, MD, PhD This podcast reviews the International Psoriasis Council (IPC) 2025 guidance on reclassifying psoriasis severity and redefining failure of topical therapies. Clinical features such as high-impact disease sites, failure of topical treatment, or BSA >10% all factor into whether patients are candidates for systemic therapy in this new guidance. Despite broad endorsement, many clinicians remain uncertain about applying

00:10:30

Engaging Your Patient: Shared Decision-Making in HF...

CME ·

2025/11/18

Faculty: Scott Solomon, MD Enhance your ability to apply shared decision-making in patients with HF and LVEF ≥40%. Through real-world clinical vignettes, Dr. Scott Solomon illustrates how to uncover patient goals, clearly communicate risks and benefits, and build collaborative treatment plans. The session emphasizes early use of SGLT2 inhibitors and finerenone to reduce hospitalizations, improve quality of life, and optimize long-term outcomes.

00:07:00

Looking Ahead: Integrating CDH6-Targeted Therapies...

CME ·

2025/11/14

Faculty: Joyce F. Liu, MD, MPH Faculty: Kathleen Moore, MD, MS Platinum-resistant ovarian cancer remains a major clinical challenge, characterized by high recurrence rates, limited durable treatment options, and poor overall survival outcomes. Cadherin-6 (CDH6)-targeted antibody-drug conjugates (ADCs) represent a novel therapeutic approach that leverages the tumor-specific expression of CDH6 to deliver potent cytotoxic agents directly to cancer cells while sparing healthy tissue

00:06:45

Clinical Evidence: Insights From Early Trials of...

CME ·

2025/11/14

Faculty: Joyce F. Liu, MD, MPH Platinum-resistant ovarian cancer remains a major clinical challenge, characterized by high recurrence rates, limited durable treatment options, and poor overall survival outcomes. Cadherin-6 (CDH6)-targeted antibody-drug conjugates (ADCs) represent a novel therapeutic approach that leverages the tumor-specific expression of CDH6 to deliver potent cytotoxic agents directly to cancer cells while sparing healthy tissue. Two such agents, raludotatug

00:29:30

The Fifth Pillar? Closing the Gap in HFrEF

CME ·

2025/11/14

Faculty: Carolyn S. P. Lam, MBBS, PhD, MRCP, MS, FACC, FAMS, FESC Faculty: Javed Butler, MD Faculty: Stephen J. Greene, MD, FACC, FHFSA For patients with heart failure with reduced ejection fraction (HFrEF), optimizing therapy is an important part of treatment and care. But not all patients may be reaching their treatment goals and can continue to face substantial residual risk despite the use of quadruple pharmacologic guideline-directed medical therapy (GDMT) and medical

00:06:15

MOA: CDH6-Targeted Antibody-Drug Conjugates

CME ·

2025/11/14

Faculty: Kathleen Moore, MD, MS Platinum-resistant ovarian cancer remains a major clinical challenge, characterized by high recurrence rates, limited durable treatment options, and poor overall survival outcomes. Cadherin-6 (CDH6)-targeted antibody-drug conjugates (ADCs) represent a novel therapeutic approach that leverages the tumor-specific expression of CDH6 to deliver potent cytotoxic agents directly to cancer cells while sparing healthy tissue. Two such agents, raludotatug

00:07:15

Safety and Tolerability of CDH6-Directed...

CME ·

2025/11/14

00:05:30

Navigating the Therapeutic Landscape of...

CME ·

2025/11/14

00:16:15

Treating MASH With Compensated Cirrhosis: A Serious...

CME ·

2025/11/11

Faculty: Naim Alkhouri, MD, FAASLD, DABOM Metabolic dysfunction-associated steatohepatitis (MASH) with compensated cirrhosis is associated with poor prognosis due to a high risk of hepatic decompensation, hepatocellular carcinoma, cardiovascular events, and death. Using noninvasive diagnostic tools like FIB-4, VCTE, and Agile 4, clinicians can accurately identify cirrhosis and clinically significant portal hypertension without the need for biopsy. Management focuses on preventing

00:42:00

Advancing Clinical Expertise in CELMoDs: Transforming...

CME ·

2025/11/10

Guest: Joshua Richter, MD This activity will cultivate familiarity with the emerging CELMoD treatment class poised to transform the management of newly-diagnosed and R/R MM. With a higher affinity for cereblon than their predecessors, CELMoDs represent a new, distinct generation of immunomodulatory drugs with the potential to bridge longstanding treatment gaps for patients exhibiting inadequate responses to the conventional medications. This activity will help providers differentiate

00:22:30

The Hidden Threat: Transforming CKD Care Across the...

CME ·

2025/11/05

Faculty: prof. Hiddo Heerspink Faculty: Peter Rossing, MD, DMSc Faculty: Paola Fioretto, MD Chronic kidney disease (CKD) is a common complication in type 2 diabetes that is closely linked to cardiovascular risk and often diagnosed late. Early detection with UACR and eGFR, plus treatment with therapies such as SGLT2 inhibitors, finerenone, and GLP-1 receptor agonists, has transformed treatment and guideline recommendations. Attention is now shifting to CKD in type 1 diabetes

00:52:15

Not Just a Headache: Migraine Across Women’s Lifespan

CME ·

2025/10/23

Faculty: Jelena Pavlović, MD, PhD Faculty: Amaal J. Starling, MD, FAHS, FAAN This session from WHAV 2025 explores the complex interplay between hormonal changes and migraine pathophysiology in women, from menarche through menopause. Faculty review diagnostic frameworks, including ICHD-3 criteria, and emphasize menstrual migraine subtypes and the role of estrogen withdrawal. Evidence-based strategies for acute and preventive treatment are discussed, including the use of CGRP

00:59:00

Women’s Sleep Health – Addressing Gaps in OSA...

CME ·

2025/10/15

Faculty: Alison Kole Faculty: Ghada Bourjeily, MD, FCCP Faculty: Rashmi Nisha Aurora, MD Faculty: Audrey Wells, MD This WHAV 2025 session addresses obstructive sleep apnea (OSA) in women, highlighting how phenotype and risk factors shift across life stages. Experts discuss how varying phenotypes contribute to delayed diagnosis and review screening tools, referral strategies, evidence linking OSA to cardiometabolic risks in menopause and pregnancy and available treatment

00:09:33

Real-World IgAN: A Case-Based Approach to Maximizing...

CME ·

2025/10/03

Host: An De Vriese, MD, PhD Faculty: Muh Geot Wong, MBBS, PhD Join Drs. An de Vriese and Muh Geot Wong in a case-based discussion on optimizing long-term kidney outcomes in patients with IgA nephropathy (IgAN). Faculty review the new KDIGO guidelines, including more aggressive treatment targets such as proteinuria levels below 0.3 g/day. A clinical case is used to illustrate practical guideline application, highlighting the use of sparsentan in a patient with persistent proteinuria

00:00:00

Test Your Skills and Learn From Experts on IL-13...

CME ·

2025/10/03

Host: Andrew F. Alexis, MD, MPH Guest: Daniel C. Butler, MD Guest: Shawn G. Kwatra, MD Watch an expert-led case discussion on the role of IL-13 in moderate to severe atopic dermatitis and the efficacy on its inhibition through biologic therapies to achieve control.

00:00:00

Pivotal Data in Anti-PD-1 Strategies for...

CME ·

2025/09/30

Faculty: James M. Cleary, MD, PhD This activity examines first-line treatment strategies for advanced HER2-negative upper gastrointestinal cancers. Expert commentary highlights the role of biomarker testing, including PD-L1 CPS and CLDN18.2, in guiding therapeutic decisions. Key clinical trial data on anti-PD-1 therapies such as nivolumab, pembrolizumab, and tislelizumab are discussed, along with regimen-specific adverse event profiles. Patient case examples illustrate the application

00:00:00

Distinguishing First-Line Treatment Adverse Event...

CME ·

2025/09/30

00:00:00

Guideline Recommendations in First-Line Treatment of...

CME ·

2025/09/30

00:00:00

Quick Case: Strategizing Treatment Selection in...

CME ·

2025/09/30

00:00:00

Clinical Criteria and Imaging Strategies for...

CME ·

2025/09/26

Faculty: Luis Paz-Ares, MD, PhD This online CME program will provide the latest clinical updates on B7-H3–directed antibody-drug conjugates (ADCs) in extensive-stage small cell lung cancer (ES-SCLC). Faculty experts will review the biological rationale for targeting B7-H3 in ES-SCLC and discuss recent clinical evidence on B7-H3 ADCs presented at WCLC and ESMO 2025. Participants will gain practical insights on selecting appropriate patients for B7-H3 ADCs, including efficacy and safety

379 results

CME

All Episodes

Similar Podcasts

科学史评话最新专辑

科学史评话

Hablando con Científicos - Cienciaes.com

cienciaes.com

天方烨谈

基因频道

The Permaculture Podcast

Scott Mann

汪诘：科学有故事（主打）

科学有故事